Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Royal Bank of Canada
Analysts at Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report ...
Seeking Alpha17 天
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows ...
Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates
Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...
Yahoo Finance2 天
Dyne Therapeutics, Inc. (DYN)
After hours: November 22 at 4:48 PM EST Loading Chart for DYN ...
Dyne Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Luca Issi initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $45 price target. Dyne’s lead program ...
Eagle-Tribune17 天
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform, the potential of DYNE-101 and DYNE-251 ...
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of “Buy” from Analysts
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given a consensus rating of “Buy” by the ten ratings firms ...
Yahoo Finance2 天
Dyne Therapeutics, Inc. (DYN)
After hours: November 27 at 5:54 p.m. EST ...